Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Ergomed PLC    ERGO   GB00BN7ZCY67

ERGOMED PLC

(ERGO)
  Report  
Delayed Quote. Delayed London Stock Exchange - 07/19 11:35:25 am
299 GBp   +0.67%
07/11ERGOMED : Dr Jim Esinhart, Former CEO of Chiltern International, Proposed Appointment as Non-Executive Director
AQ
07/10ERGOMED : Board Appointment
PU
06/19ERGOMED : Share Options
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
07/15/2019 07/16/2019 07/17/2019 07/18/2019 07/19/2019 Date
273(c) 273(c) 293(c) 297(c) 299(c) Last
18 473 2 182 895 561 874 11 850 236 102 Volume
+1.11% 0.00% +7.33% +1.37% +0.67% Change
More quotes
Financials (GBP)
Sales 2019 64,3 M
EBIT 2019 6,48 M
Net income 2019 3,30 M
Finance 2019 9,45 M
Yield 2019 -
Sales 2020 71,6 M
EBIT 2020 8,00 M
Net income 2020 4,40 M
Finance 2020 15,1 M
Yield 2020 -
P/E ratio 2019 41,5x
P/E ratio 2020 32,2x
EV / Sales2019 2,02x
EV / Sales2020 1,74x
Capitalization 140 M
More Financials
Company
Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring... 
More about the company
Surperformance© ratings of Ergomed PLC
Trading Rating : - Investor Rating :
More Ratings
Latest news on ERGOMED PLC
07/11ERGOMED : Dr Jim Esinhart, Former CEO of Chiltern International, Proposed Appoin..
AQ
07/10ERGOMED : Board Appointment
PU
06/19ERGOMED : Share Options
PU
06/18ERGOMED : Board Appointment
PU
06/10ERGOMED : PDMR Dealing
PU
06/05ERGOMED : Strengthens Executive Team with Appointment of Richard Barfield, Forme..
AQ
06/04ERGOMED : Appointment of CFO
PU
06/03ASARINA PHARMA PUBL : issues new shares to Ergomed plc
AQ
05/31ERGOMED : Ergomed and Prime Vigilance Latest Free Webinar
AQ
05/28ERGOMED : 2019 ASCO Annual Meeting
AQ
More news
Analyst Recommendations on ERGOMED PLC
More recommendations
Sector news : Bio Therapeutic Drugs
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/17GILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave
DJ
07/16As steep patent cliff looms, Shionogi moves to develop its own U.S. sales sta..
RE
07/16GSK's two-drug HIV Dovato treatment meets main goal in study
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
More sector news : Bio Therapeutic Drugs
Chart ERGOMED PLC
Duration : Period :
Ergomed PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERGOMED PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 277,50  GBp
Last Close Price 299,00  GBp
Spread / Highest target -3,68%
Spread / Average Target -7,19%
Spread / Lowest Target -10,7%
EPS Revisions
Managers
NameTitle
Miroslav Reljanovic Executive Chairman
Jan Petracek Chief Operating Officer & Executive Director
Stuart Robert Jackson Chief Financial Officer & Director
Peter Lutz George Senior Independent Non-Executive Director
Christopher Irvin Collins Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ERGOMED PLC90.45%175
GILEAD SCIENCES3.98%82 702
VERTEX PHARMACEUTICALS7.47%44 598
REGENERON PHARMACEUTICALS-20.18%32 544
GENMAB14.94%11 908
SAREPTA THERAPEUTICS INC36.77%11 068